AI Summary
This grant opportunity, RFA-HL-26-017 (Catalyze), focuses on product definition for small molecules, biologics, and combination products, specifically target identification and validation, and preliminary product/lead series identification. Clinical trials are not allowed under this R61/R33 mechanism. The funding opportunity is associated with CFDA numbers 93.839, 93.838, 93.233, and 93.837.